Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.51% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTOrganogenesis Holdings Inc.'s latest supported as-filed period reports revenue of $43.8M, 56.7% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.51% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -72.34% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -56.68% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 66.92% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -116.54% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 41.82% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -36.9% from the comparable as-filed period.
Inventory changed -11.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Net income changed -925.0% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ORGO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-338321SEC ↗10-QAug 6, 2026Period Jun 30, 20260001193125-26-338049SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-338022SEC ↗8-KJun 16, 2026Period Jun 15, 20260001193125-26-272710SEC ↗10-QMay 7, 2026Period Mar 31, 20260001661181-26-000008SEC ↗8-KMay 7, 2026Period May 7, 20260001661181-26-000007SEC ↗4Apr 24, 2026Period Jan 10, 20250002064832-26-000183SEC ↗4Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 6.98% · OPTIONAL
Operating income changed -305.5% from the comparable as-filed period.
Operating margin changed -10409 basis points from the comparable as-filed period.
Research & development changed +76.0% from the comparable as-filed period.
Revenue changed -56.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0002064832-26-000129